Sarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...

And even after the significant gains it has experienced in recent years, it might still be early enough to get on the ...

Investors who bought WeBull (BULL) before last week gained 33.6%. However, after the market closed on Friday, July 18, the ...

Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

Every so often, activist investors swarm around underperforming companies in a certain industry and pressure them to change ...

Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable ...

Top experts from Amgen, CBIZ & Intrepid discuss 2025 trends in healthcare, biotech, and life sciences. Explore key insights ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...

IPOs launching include Shanti Gold, Patel Chem, Brigade Hotel, Indiqube Spaces, GNG Electronics, Swastika Castal, and Monarch Surveyors.

WY Biotech is now obligated to pay a $7 million upfront license fee to HCW Biologics by Sept. 30, according to a filing with the Securities and Exchange Commission. HCW Biologics previously said it ...